Giacomo G Baldi, Co-Founder of GAPMED and Zerynth, shared a post on X:
”Another outstanding presentation by Sydney Stern on the TGCT patient registry data!
Collaboration between patient advocates and clinicians is essential to overcoming disparities in TGCT.
Thank you, Sydney Stern, for your effort and enthusiasm!”
You can also read: FDA approves Vimseltinib(Romvimza) for symptomatic Tenosynovial Giant Cell Tumor (TGCT)
